Malaysian Orphan Medicines Guideline 2020

The Ministry of Health (MOH) Malaysia recognises the needs of the patients with rare diseases in Malaysia. Under the Malaysian National Medicines Policy (MNMP) one of the focus areas to improve on is to enhance the accessibility of life-saving products and orphan medicines without compromising safety, quality and efficacy of the medicines.

The purpose of this guideline is to facilitate access to medicines required for the management of rare diseases in the context of the Ministry, based on a consensus list of rare diseases compiled through consultation with rare disease experts.